Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANNA HALPERN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1952531790
CMS profile
704057
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,539.93

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
SOBI, INC $3,884.93 1
Karyopharm Therapeutics Inc. $1,700.00 1
E.R. Squibb & Sons, L.L.C. $955.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANNA HALPERN

NPI 1952531790 · CMS profile ID 704057

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952531790?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANNA HALPERN, NPI 1952531790, CMS profile ID 704057. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952531790?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANNA HALPERN, NPI 1952531790, CMS profile ID 704057. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952531790?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANNA HALPERN, NPI 1952531790, CMS profile ID 704057, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1952531790?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $6,539.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SOBI, INC $3,884.9309/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240286556 CMS
E.R. Squibb & Sons, L.L.C. $955.0008/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184872678 CMS
Karyopharm Therapeutics Inc. $1,700.0007/15/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1246642412 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $3,300.00 1
PY2021 $1,660.00 2
PY2022 $585.67 2
PY2023 $1,223.26 3
PY2024 $277.32 5
PY2025 $6,539.93 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $827,949.32 641
PY2024 Principal investigator $566,406.00 261
PY2023 Principal investigator $102,938.19 71
PY2022 Principal investigator $588,631.39 40
PY2021 Principal investigator $751,174.50 8
PY2020 Principal investigator $363,188.60 3
PY2019 Principal investigator $200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $705.00 12/21/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225161
Principal investigator 1 Incyte Corporation $5,544.90 12/14/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225163
Principal investigator 1 Incyte Corporation $2,705.40 12/14/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225165
Principal investigator 1 Incyte Corporation $11,475.00 12/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225159
Principal investigator 1 Incyte Corporation $4,183.20 11/09/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216603
Principal investigator 1 Incyte Corporation $11,376.00 11/09/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225155
Principal investigator 1 Incyte Corporation $18,000.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216589
Principal investigator 1 Incyte Corporation $6,850.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216591
Principal investigator 1 Incyte Corporation $4,142.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216593
Principal investigator 1 Incyte Corporation $1,905.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216595
Principal investigator 1 Incyte Corporation $3,175.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216597
Principal investigator 1 Incyte Corporation $1,436.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216599
Principal investigator 1 Incyte Corporation $1,905.00 11/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905216605
Principal investigator 1 Incyte Corporation $12,235.50 10/19/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225153
Principal investigator 1 Incyte Corporation $1,053.93 10/05/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225149
Principal investigator 1 Karyopharm Therapeutics Inc. $7,172.00 10/04/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1058948315
Principal investigator 1 Incyte Corporation $25,953.30 08/10/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225145
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180,500.00 06/24/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
CPX-351 OR CLAG-M REGIMEN FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA OR OTHER HIGH-GRADE MYELOID NEOPLASMS IN MEDICALLY LESS-FIT PATIENTS No dispute reported 06/30/2026 950279053
Principal investigator 1 Incyte Corporation $10,353.60 06/22/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225111
Principal investigator 1 Incyte Corporation $67.60 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225115
Principal investigator 1 Incyte Corporation $2.84 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225117
Principal investigator 1 Incyte Corporation $35.16 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225119
Principal investigator 1 Incyte Corporation $5.44 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225121
Principal investigator 1 Incyte Corporation $20.26 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225123
Principal investigator 1 Incyte Corporation $20.42 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225125
Principal investigator 1 Incyte Corporation $3.04 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225127
Principal investigator 1 Incyte Corporation $30.92 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225129
Principal investigator 1 Incyte Corporation $7.16 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225131
Principal investigator 1 Incyte Corporation $0.60 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225133
Principal investigator 1 Incyte Corporation $110.10 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225135
Principal investigator 1 Incyte Corporation $2.00 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225137
Principal investigator 1 Incyte Corporation $67.60 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225139
Principal investigator 1 Incyte Corporation $20.42 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225141
Principal investigator 1 Incyte Corporation $67.60 06/08/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 905225143
Principal investigator 1 Karyopharm Therapeutics Inc. $51,604.00 06/07/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications No dispute reported 06/30/2026 1058948307
Principal investigator 1 Incyte Corporation $23,135.40 04/13/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225105
Principal investigator 1 Incyte Corporation $4,140.00 03/23/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225103
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,518.00 03/08/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II MULTI-CENTER STUDY OF INTRAVENOUS MBG453 ADDED TO HYPOMETHYLATING AGENTS IN ADULT SUBJECTS WITH INTERMEDIATE, HIGH OR VERY HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) AS PER IPSS-R CRITERIA (STIMULUS-MD No dispute reported 06/30/2026 909386791
Principal investigator 1 Incyte Corporation $10,602.00 02/16/2022 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 905225095
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180,500.00 02/01/2022 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
CPX-351 OR CLAG-M REGIMEN FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA OR OTHER HIGH-GRADE MYELOID NEOPLASMS IN MEDICALLY LESS-FIT PATIENTS No dispute reported 06/30/2026 950279051